Galecto (GLTO) Competitors $3.53 +0.06 (+1.61%) Closing price 07/11/2025 03:55 PM EasternExtended Trading$3.52 0.00 (-0.03%) As of 07/11/2025 06:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock GLTO vs. CING, MRKR, BIVI, QTTB, MTEX, PRPH, RVPH, CARM, LPCN, and GELSShould you be buying Galecto stock or one of its competitors? The main competitors of Galecto include Cingulate (CING), Marker Therapeutics (MRKR), BioVie (BIVI), Q32 Bio (QTTB), Mannatech (MTEX), ProPhase Labs (PRPH), Reviva Pharmaceuticals (RVPH), Carisma Therapeutics (CARM), Lipocine (LPCN), and Gelteq (GELS). These companies are all part of the "pharmaceutical products" industry. Galecto vs. Its Competitors Cingulate Marker Therapeutics BioVie Q32 Bio Mannatech ProPhase Labs Reviva Pharmaceuticals Carisma Therapeutics Lipocine Gelteq Cingulate (NASDAQ:CING) and Galecto (NASDAQ:GLTO) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, media sentiment, valuation, dividends and profitability. Is CING or GLTO more profitable? Galecto's return on equity of -98.27% beat Cingulate's return on equity.Company Net Margins Return on Equity Return on Assets CingulateN/A -229.78% -142.28% Galecto N/A -98.27%-84.29% Which has more volatility & risk, CING or GLTO? Cingulate has a beta of -0.79, meaning that its stock price is 179% less volatile than the S&P 500. Comparatively, Galecto has a beta of 1.35, meaning that its stock price is 35% more volatile than the S&P 500. Do institutionals & insiders hold more shares of CING or GLTO? 41.3% of Cingulate shares are held by institutional investors. Comparatively, 14.2% of Galecto shares are held by institutional investors. 5.3% of Cingulate shares are held by insiders. Comparatively, 10.8% of Galecto shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has better valuation & earnings, CING or GLTO? Cingulate is trading at a lower price-to-earnings ratio than Galecto, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCingulateN/AN/A-$15.55M-$8.48-0.51GalectoN/AN/A-$21.44M-$15.53-0.23 Does the media prefer CING or GLTO? In the previous week, Cingulate had 1 more articles in the media than Galecto. MarketBeat recorded 5 mentions for Cingulate and 4 mentions for Galecto. Cingulate's average media sentiment score of 0.63 beat Galecto's score of -0.03 indicating that Cingulate is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cingulate 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Galecto 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend CING or GLTO? Cingulate presently has a consensus price target of $26.00, suggesting a potential upside of 497.70%. Galecto has a consensus price target of $10.00, suggesting a potential upside of 183.61%. Given Cingulate's higher possible upside, equities analysts clearly believe Cingulate is more favorable than Galecto.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cingulate 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Galecto 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryCingulate beats Galecto on 7 of the 12 factors compared between the two stocks. Get Galecto News Delivered to You Automatically Sign up to receive the latest news and ratings for GLTO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GLTO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GLTO vs. The Competition Export to ExcelMetricGalectoMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.67M$2.94B$5.56B$9.11BDividend YieldN/A2.42%5.06%4.01%P/E Ratio-0.2320.8528.2320.27Price / SalesN/A298.79434.20100.92Price / CashN/A42.1137.1257.67Price / Book0.327.638.045.49Net Income-$21.44M-$55.05M$3.19B$250.45M7 Day Performance2.20%8.43%3.62%4.78%1 Month Performance5.25%8.14%5.98%9.58%1 Year Performance-74.12%1.62%29.39%16.41% Galecto Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GLTOGalecto3.2692 of 5 stars$3.53+1.6%$10.00+183.6%-74.1%$4.67MN/A-0.2340CINGCingulate3.1113 of 5 stars$4.42+3.3%$26.00+488.2%+911.6%$18.17MN/A-0.5220News CoverageMRKRMarker Therapeutics4.5297 of 5 stars$1.57-1.9%$13.17+738.6%-67.3%$18.10M$6.59M-1.1860News CoverageBIVIBioVie1.0767 of 5 stars$8.10-15.6%N/A+53.9%$17.83MN/A-1.0210News CoveragePositive NewsQTTBQ32 Bio2.7079 of 5 stars$1.36-5.6%$12.17+794.6%-89.9%$17.57M$1.16M-0.2839Gap DownMTEXMannatech1.3938 of 5 stars$8.90-3.8%N/A+19.0%$17.49M$117.87M-89.00250High Trading VolumePRPHProPhase Labs0.6739 of 5 stars$0.44+5.6%N/A-87.1%$17.39M$5.85M-0.35130Positive NewsRVPHReviva Pharmaceuticals2.9248 of 5 stars$0.37+1.9%$9.00+2,353.0%-68.5%$17.28MN/A-0.465Gap UpCARMCarisma Therapeutics2.9745 of 5 stars$0.40-2.0%$1.93+387.3%-66.7%$16.84M$19.63M-0.2520LPCNLipocine2.5618 of 5 stars$3.11+0.3%$9.00+189.4%-57.5%$16.59M$11.20M-3.0510GELSGelteqN/A$1.67-2.9%N/AN/A$16.23M$100K0.00N/AGap Down Related Companies and Tools Related Companies Cingulate Competitors Marker Therapeutics Competitors BioVie Competitors Q32 Bio Competitors Mannatech Competitors ProPhase Labs Competitors Reviva Pharmaceuticals Competitors Carisma Therapeutics Competitors Lipocine Competitors Gelteq Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GLTO) was last updated on 7/13/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galecto, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Galecto With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GLTO Stock Alerts